{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:28:46Z","timestamp":1756189726616,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010881","name":"Suzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>BRAF non-V600 mutations are a distinct molecular subset of colorectal cancer (CRC) that has little to no clinical similarity to the BRAF V600 mutations. It is generally considered that the BRAF non-V600 mutations correlate with better survival of CRC patients. In this report, we present an unusual case of that a midlife female patient who was initially diagnosed with stage IIIC colon cancer, and multiple metastases were found 25 months after radical surgery. Next-generation sequencing (NGS) revealed the BRAF p.N581I (c.1742A&amp;gt;T) mutation. She received chemotherapy, targeted therapy, and immunotherapy. However, the disease progressed rapidly with rare metastasis of the bone and cerebellum. This case highlights that the BRAF non-V600 mutations, such as BRAF p.N581I mutant, may lead to resistance to epidermal growth factor receptor (EGFR) inhibitors and result in a rapid course in colorectal cancer. The role of BRAF p.N581I mutation in colorectal cancer demands more attention.<\/jats:p>","DOI":"10.3389\/fonc.2023.1175693","type":"journal-article","created":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T03:21:00Z","timestamp":1689391260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Multidrug resistance in the standardized treatment of colon cancer harboring a rare fibrosarcoma B-type (BRAF) p.N581I mutation: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133252","article-title":"A ras-independent biomarker panel to reliably predict response to mek inhibition in colorectal cancer","volume":"14","author":"Pfohl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09913-7","article-title":"Current therapy of advanced colorectal cancer according to Ras\/Raf mutational status","volume":"39","author":"Lakatos","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B3","article-title":"The prognostic value of kras and braf in stage I-iii colorectal cancer","volume":"90","author":"Gallo","year":"2019","journal-title":"A Systematic Review. Ann Ital Chir"},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jss.2018.06.020","article-title":"Clinical significance of braf non-V600e mutations in colorectal cancer: a retrospective study of two institutions","volume":"232","author":"Shimada","year":"2018","journal-title":"J Surg Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02541","article-title":"Braf-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape","volume":"40","author":"Ciombor","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00736-1","article-title":"Therapeutic landscape and future direction of metastatic colorectal cancer","volume":"20","author":"Bando","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0365-2","article-title":"The dimer-dependent catalytic activity of raf family kinases is revealed through characterizing their oncogenic mutants","volume":"37","author":"Yuan","year":"2018","journal-title":"Oncogene"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I-iii braf mutations among 114,662 cancer patients in a Large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174067","article-title":"Braf mutations in colorectal liver metastases: prognostic implications and potential therapeutic strategies","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy477","article-title":"Activity of egfr antibody in non-V600 braf mutant metastatic colorectal cancer","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215369","article-title":"Braf-mutated colorectal cancer: clinical and molecular insights","volume":"20","author":"Caputo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00443-8","article-title":"The clinical and genomic distinctions of Class1\/2\/3 braf-mutant colorectal cancer and differential prognoses","volume":"11","author":"Chen","year":"2023","journal-title":"biomark Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.4394","article-title":"(Non-V600) braf mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0311","article-title":"Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: a detailed clinical, pathologic, and molecular characterization","volume":"25","author":"Schirripa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of braf in cancer therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2004","article-title":"Response to anti-egfr therapy in patients with braf non-V600-Mutant metastatic colorectal cancer","volume":"25","author":"Yaeger","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00195","article-title":"Targeted therapy for colorectal cancers with non-V600 braf mutations: perspectives for precision oncology","author":"Dankner","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.140","article-title":"Cell signalling: even kinase-inactive braf is oncogenic","volume":"14","author":"Killock","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0012-2","article-title":"Comment on 'Clinical significance of braf non-V600e mutations on the therapeutic effects of anti-egfr monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the biomarker research for anti-egfr monoclonal antibodies by comprehensive cancer genomics (Breac) study'","volume":"118","author":"Dankner","year":"2018","journal-title":"Br J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, nccn clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase ib trial (Regonivo, Epoc1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-3539","article-title":"Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review","volume":"11","author":"Xu","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.20.5396","article-title":"Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner","volume":"19","author":"Davy","year":"2000","journal-title":"EMBO J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab028","article-title":"Mucinous histology is associated with resistance to anti-egfr therapy in patients with left-sided Ras\/Braf wild-type metastatic colorectal cancer","volume":"27","author":"Wang","year":"2022","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22943","article-title":"Lkb1 loss cooperating with braf V600e promotes melanoma cell invasion and migration by up-regulation mmp-2 Via Pi3k\/Akt\/Mtor pathway","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.004","article-title":"Acquired braf N581s mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib","volume":"146","author":"Liu","year":"2020","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class Erk1\/2 inhibitor ulixertinib (Bvd-523) in patients with mapk mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discovery"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1175693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T03:21:05Z","timestamp":1689391265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1175693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":27,"alternative-id":["10.3389\/fonc.2023.1175693"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1175693","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,7,14]]},"article-number":"1175693"}}